ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag office politics disease medicine ecology

A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Quickening the Diagnosis of Mad Cow Disease
Laura Defrancesco | Jun 10, 2001 | 6 min read
Europeans have destroyed 4.5 million cows since 1996, the height of the epidemic in the United Kingdom, because they were believed to be at risk for mad cow disease (bovine spongiform encephalopathy, or BSE).1 Necropsies, however, showed that only a few hundred thousand of them actually were infected.2 Had a diagnostic test for mad cow disease existed when this epidemic erupted, these numbers might have been different. But no such test did exist. The only available assay was a bioassay in which
Antibody Alternatives
Paul Ko Ferrigno and Jane McLeod | Feb 1, 2016 | 10+ min read
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
Steps to End “Colonial Science” Slowly Take Shape
Ashley Yeager | Jan 1, 2021 | 10 min read
Scientists from countries with fewer resources are pushing collaborators from higher-income countries to shed biases and behaviors that perpetuate social stratification in the research community.
Happenings
The Scientist Staff | Jul 12, 1987 | 7 min read
R. Palmer Beasley, known for his work that linked the hepatitis B virus to liver cancer, has been appointed dean of the University of Texas School of Public Health in Houston. Beasley is currently professor of medicine and head of the Division of Communicable Disease Epidemiology at the University of California at San Francisco. He is also director of the American University Medical Center in Taipei, Taiwan, a position he will continue to hold after his move to Houston. Mitchell Feigenbaum has
Updated Sept 1
coronavirus pandemic news articles covid-19 sars-cov-2 virology research science
Follow the Coronavirus Outbreak
The Scientist | Feb 20, 2020 | 10+ min read
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system
AIDS Researchers, Activists Wary Of Newspaper Article's Message
Steven Benowitz | Jun 9, 1996 | 10+ min read
Despite contrary suggestions, they say CDC's prevention efforts aimed toward general public were not wasted A recent article in the Wall Street Journal is causing concern in the AIDS research community. The article, titled "AIDS Fight Is Skewed By Federal Campaign Exaggerating Risks" (A. Bennett, A. Sharpe, May 1, 1996, page 1), contends that the federal Centers for Disease Control and Prevention (CDC) in Atlanta has distorted the public's perception of the potential for contracting AIDS with a
Notebook
The Scientist Staff | Oct 29, 1995 | 6 min read
ON THE BLOCK: An Ig Nobel celebrant won a date with Nobelist Dudley Herschbach. The Annals of Improbable Research followed tradition in its "Fifth First Annual Ig Nobel Prize Ceremony," honoring the 1995 Ig Nobel laureates with its own special version of pomp. Prizes-awarded to those whose achievements "cannot or should not be reproduced"-were presented by Nobelists Sheldon Glashow (physics 1979), Dudley Herschbach (chemistry 1986), Joseph Murray (physiology or medicine 1990), and Richard Robe
African Sleeping Sickness: A Recurring Epidemic
Ricki Lewis | May 12, 2002 | 5 min read
African trypanosomiasis is making an unwelcome comeback. But unlike other returning diseases, this one has a drug treatment—eflornithine—that disappeared from the market when it failed to cure cancer. Yet like Viagra's origin from a curious side effect in a clinical trial, so too was eflornithine reborn. "When it was discovered that it removes mustaches in women, it suddenly had a market: western women with mustaches," says Morten Rostrup, president of the international council for M
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s

Run a Search

ADVERTISEMENT